UM  > 健康科學學院
An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes
Zhang Cheng1; Yanbo Yuan1; Xue Han1; Shangli Cai2; Fude Yang3; Zheng Lu4; Chuanyue Wang5; Hong Deng6; Jingping Zhao2; Yutao Xiang7; Christoph U Correll8,9,10,11; Xin Yu1
2019-09
Source PublicationJOURNAL OF PSYCHOPHARMACOLOGY
ISSN0269-8811
Volume33Issue:10Pages:1227-1236
AbstractPurpose: This study aimed to investigate the efficacy and tolerability of aripiprazole, olanzapine and risperidone in first-episode schizophrenia (FES). Methods: The eight-week, open, randomised study was conducted in six Chinese medical centres. Altogether, 498 FES subjects were randomised to aripiprazole (n = 165), olanzapine (n = 168) or risperidone (n = 165). Efficacy was measured with the Positive and Negative Syndrome Scale (PANSS), tolerability with the Udvalg for Kliniske Undersogelser Side Effect Rating Scale (UKU) and functioning with the Personal and Social Performance Scale (PSP). Results: All three antipsychotics significantly improved the baseline to end-point PANSS total and each of the sub-scale scores (p < 0.001). Risperidone was superior to olanzapine and aripiprazole regarding PANSS total end-point scores (p < 0.05). Cumulative response (PANSS total score reduction ⩾30%) was similar between risperidone, olanzapine and aripiprazole (74.8%, 73.5% and 70.1%; p = 0.707), but risperidone was superior to aripiprazole regarding PANSS total score reduction ⩾50% (37.8% vs. 26.6%; p < 0.05). Olanzapine was associated with the largest weight gain at week 4 and 8 (p < 0.01), weight gain ⩾7% (olanzapine = 49.0% vs. risperidone = 32.5% vs. aripiprazole = 17.0%; p < 0.01), more psychic side effects at week 8 (p < 0.01 each) and more ‘other’ side effects at week 4 (p < 0.001) and week 8 (p < 0.05) but fewer neurological side effects at week 4 (p < 0.05) and week 8 (p < 0.01). PSP improved more with risperidone than with aripiprazole at week 4 and 8 (p < 0.05). Conclusions: For FES, risperidone might be a better choice than aripiprazole due to improved efficacy and functional improvement, without inferior tolerability. Aripiprazole is a better choice to avoid relevant short-term weight gain. Olanzapine could be chosen to avoid neurological adverse effects.
KeywordFirst-episode Schizophrenia Antipsychotic Efficacy Safety
DOI10.1177/0269881119872193
Indexed BySCI
Language英语
WOS Research AreaNeurosciences & Neurology ; Pharmacology & Pharmacy ; Psychiatry
WOS SubjectClinical Neurology ; Neurosciences ; Pharmacology & Pharmacy ; Psychiatry
WOS IDWOS:000485447200001
Fulltext Access
Citation statistics
Cited Times [WOS]:0   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionFaculty of Health Sciences
Affiliation1.Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Centre for Mental Disorders (Peking University Sixth Hospital), Beijing, PR China
2.Mental Health Institute, Second Xiangya Hospital, Central South University, Changsha, PR China
3.Beijing Hui-Long-Guan Hospital, Beijing, PR China
4.Tongji Hospital of Tongji University, Shanghai, PR China
5.Beijing Anding Hospital, Capital Medical University, Beijing, PR China
6.West China Hospital, Sichuan University, Chengdu, PR China
7.Unit of Psychiatry, Faculty of Health Science, University of Macau, Macao SAR, PR China
8.The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA
9.Hofstra Northwell School of Medicine, Hempstead, NY, USA
10.Charité Universitätsmedizin, Department of Child and Adolescent Psychiatry, Berlin, Germany
11.Investigator, Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA
Recommended Citation
GB/T 7714
Zhang Cheng,Yanbo Yuan,Xue Han,et al. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes[J]. JOURNAL OF PSYCHOPHARMACOLOGY,2019,33(10):1227-1236.
APA Zhang Cheng.,Yanbo Yuan.,Xue Han.,Shangli Cai.,Fude Yang.,...&Xin Yu.(2019).An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes.JOURNAL OF PSYCHOPHARMACOLOGY,33(10),1227-1236.
MLA Zhang Cheng,et al."An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes".JOURNAL OF PSYCHOPHARMACOLOGY 33.10(2019):1227-1236.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Zhang Cheng]'s Articles
[Yanbo Yuan]'s Articles
[Xue Han]'s Articles
Baidu academic
Similar articles in Baidu academic
[Zhang Cheng]'s Articles
[Yanbo Yuan]'s Articles
[Xue Han]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Zhang Cheng]'s Articles
[Yanbo Yuan]'s Articles
[Xue Han]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.